Compare Novavax Inc (NVAX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 26.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| NVAX | TLT | |
|---|---|---|
Market Cap | $1.82B | $47.61B |
Volume | 6,198,505 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $12.56 | $92.06 |
52-Week Low | $6.22 | $77.11 |
Typical Hold Time | 59 Days | 83 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, up 0.94% on the day but remains in a prolonged downtrend, down 11% year-to-date and 46% over five years. The technical picture is bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights a challenging bond market environment with Treasury yields reaching multi-decade highs, creating headwinds for long-duration bond funds.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields offering potential income but significant price risk if rates continue rising. Key investment considerations include duration risk exposure, inflation expectations, and Federal Reserve policy shifts. The fund's dividend payments provide income, but capital preservation remains challenging in the current rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
